AI and remote monitoring are shaping a new patient journey in oncology
Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting
Cancer Intelligence (eHealth, Telehealth Technology, BIG Data)
Will AI reduce or increase inequities in cancer care?
While the use of artificial intelligence systems is expanding in oncology, ethical issues including biases introduced in care delivery and uneven access to technology raise concerns about whether some patients may be left behind
Pan-cancer AI model shows to predict 30-day mortality in patients with advanced cancer
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Can AI help deliver better medicines to patients?
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
Embracing interdisciplinary collaboration for an AI-driven oncology
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
AI-driven tool shows to improve risk stratification in colorectal cancer
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
AI integration in breast cancer – a long way ahead?
Experts’ discussions during ESMO Breast 2025 provided an overview on promises and challenges in the field
Will voice-enabled AI have a role in oncology?
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Will AI reshape breast cancer screening?
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes